Vitaeris Announces Multiple Scientific Presentations Involving Clazakizumab at the 2019 American Transplant Congress

May 22, 2019
Vitaeris Inc.

Anti-Interleukin 6 Monoclonal Antibody for Antibody-Mediated Kidney Transplant Rejection  8 Oral & Poster Presentations Vancouver, Canada, May 22, 2019 – Vitaeris Inc. (Vitaeris) today announced that eight abstracts involving or related to clazakizumab, Vitaeris’ proprietary anti-interleukin-6 humanized monoclonal antibody, have been accepted for presentation at the 2019 American Transplant Congress (ATC) taking place from June … Continue reading Vitaeris Announces Multiple Scientific Presentations Involving Clazakizumab at the 2019 American Transplant Congress

DelMar Pharmaceuticals Announces Expansion of Scientific Advisory Board

May 21, 2019
DelMar Pharmaceuticals Inc.

Appoint Drs. David Reardon, Timothy Cloughesy, and Nicholas Butowski VANCOUVER, British Columbia and MENLO PARK, Calif., May 20, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced today the appointments of three additional world-class neuro-oncologists to its Scientific Advisory Board … Continue reading DelMar Pharmaceuticals Announces Expansion of Scientific Advisory Board

DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2019 Financial Results

May 15, 2019
DelMar Pharmaceuticals Inc.

Company will host a business update conference call on May 23, 2019 at 4:30 PM Eastern Time VANCOUVER, British Columbia and MENLO PARK, Calif., May 15, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new cancer therapies, announced its financial results for the third quarter ended … Continue reading DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2019 Financial Results

Arbutus to Present at Upcoming May 2019 Conferences

May 13, 2019
Arbutus Biopharma Corp.

WARMINSTER, Pa., May 13, 2019 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Mark J. Murray, Arbutus’ President and CEO, will present at the following conferences in May 2019: UBS Global Healthcare Conference                      Monday, May 20, 2019, 1:00 PM ET – New York RBC Capital Markets Healthcare Conference      … Continue reading Arbutus to Present at Upcoming May 2019 Conferences

Virogin Biotech to Form a Joint Venture with China’s Largest Pharmaceutical Company to Commercialize Oncolytic Virotherapies

May 9, 2019
Virogin Biotech

Vancouver, Canada – Virogin Biotech (“Virogin”) is pleased to announce it has recently signed an agreement with China National Biotec Group (CNBG) to create a Joint Venture that will focus on the research & development, clinical development, and commercialization of oncolytic virotherapies. The new company will be based at the Precision Medicine Industrial Park located … Continue reading Virogin Biotech to Form a Joint Venture with China’s Largest Pharmaceutical Company to Commercialize Oncolytic Virotherapies

DelMar Pharmaceuticals Announces Key Dates and Timeline for Stockholder Participation in Rights Offering

May 8, 2019
DelMar Pharmaceuticals Inc.

VANCOUVER, British Columbia and MENLO PARK, Calif., May 8, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today provided an update to stockholders regarding the Company’s rights offering and the key dates and terms relative to the offering.  Stockholders are … Continue reading DelMar Pharmaceuticals Announces Key Dates and Timeline for Stockholder Participation in Rights Offering

DelMar Pharmaceuticals Announces 1-for-10 Reverse Stock Split

May 7, 2019
DelMar Pharmaceuticals, Inc.

VANCOUVER, British Columbia and MENLO PARK, Calif., May 7, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced today that it will effect a 1-for-10 reverse stock split of its outstanding common stock. This will be effective for trading purposes … Continue reading DelMar Pharmaceuticals Announces 1-for-10 Reverse Stock Split

Xenon Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update

XENON PHARMACEUTICALS INC.

Company Reports Advancements in Neurology-Focused Pipeline and Anticipates Multiple Products in Phase 2 or Later Stage Development this Year Conference Call at 4:30 pm ET Today BURNABY, British Columbia, May 07, 2019 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today reported its financial results for the first quarter ended March 31, … Continue reading Xenon Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update

Arbutus Reports First Quarter 2019 Financial Results and Provides Corporate Update

May 6, 2019
Arbutus Biopharma Corp.

Top-line safety and efficacy results from an interim analysis of the initial Phase 1a/1b clinical trial of AB-506, a proprietary oral capsid inhibitor, expected in July 2019 Conference Call and Webcast Scheduled Today at 4:30 PM ET WARMINSTER, Pa., May 06, 2019 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, … Continue reading Arbutus Reports First Quarter 2019 Financial Results and Provides Corporate Update

DelMar Presents Data Supporting VAL-083 as Potential Treatment for Pediatric Brain Tumors at SNO Pediatric Neuro-Oncology Conference

DelMar Pharmaceuticals Inc.

VANCOUVER, British Columbia and MENLO PARK, Calif., May 6, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new cancer therapies, on May 3, 2019 presented data supporting Dianhydrogalactitol (VAL-083) as a potential therapy for pediatric brain tumors at the Society for Neuro-Oncology (SNO) Pediatric Neuro-Oncology Basic … Continue reading DelMar Presents Data Supporting VAL-083 as Potential Treatment for Pediatric Brain Tumors at SNO Pediatric Neuro-Oncology Conference